Literature DB >> 32600541

Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.

Joseph A Miccio1, Oluwadamilola T Oladeru2, Sung Jun Ma3, Kimberly L Johung4.   

Abstract

Stereotactic radiosurgery and stereotactic body radiation therapy (SBRT) have led to a resurgence of the use of radiotherapy in the management of advanced renal cell carcinoma (RCC). These techniques provide excellent local control and palliation of metastatic sites of disease with minimal toxicity. Additionally, SBRT to the primary tumor may be efficacious and well tolerated in select patients that are not surgical candidates. Emerging data suggest that SBRT may potentiate the immune response, and current and future study will evaluate if SBRT can improve survival outcomes in patients with metastatic RCC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Radiotherapy; Renal cell carcinoma; Stereotactic body radiation therapy; Stereotactic radiosurgery

Mesh:

Substances:

Year:  2020        PMID: 32600541     DOI: 10.1016/j.ucl.2020.04.011

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

1.  Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.

Authors:  Tressie Herrmann; Angeline Ginzac; Ioana Molnar; Sébastien Bailly; Xavier Durando; Hakim Mahammedi
Journal:  Cancer Med       Date:  2021-08-18       Impact factor: 4.452

2.  Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.

Authors:  Lucia Gil; Fátima R Alves; Diana Silva; Isabel Fernandes; Mário Fontes-Sousa; Marta Alves; Ana Papoila; Ricardo Da Luz
Journal:  Cureus       Date:  2022-02-15

3.  Autophagy Induced by Micheliolide Alleviates Acute Irradiation-Induced Intestinal Injury via Inhibition of the NLRP3 Inflammasome.

Authors:  Dong-Ming Wu; Jing Li; Rong Shen; Jin Li; Ye Yu; Li Li; Shi-Hua Deng; Teng Liu; Ting Zhang; Ying Xu; De-Gui Wang
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.